TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $160,750 | -48.5% | 17,981 | -11.5% | 0.10% | -47.0% |
| Q2 2023 | $311,946 | -16.8% | 20,309 | +21.8% | 0.18% | -10.2% |
| Q1 2023 | $374,998 | +8.9% | 16,674 | +1.8% | 0.21% | +14.4% |
| Q4 2022 | $344,492 | +39.5% | 16,381 | +63.5% | 0.18% | +83.7% |
| Q3 2022 | $247,000 | +3.3% | 10,019 | +1.5% | 0.10% | +10.1% |
| Q2 2022 | $239,000 | -34.3% | 9,875 | -30.0% | 0.09% | -45.4% |
| Q1 2022 | $364,000 | -16.9% | 14,116 | 0.0% | 0.16% | -1.2% |
| Q4 2021 | $438,000 | -38.8% | 14,116 | -52.2% | 0.16% | -47.6% |
| Q3 2021 | $716,000 | +52.0% | 29,543 | -8.4% | 0.32% | +62.4% |
| Q2 2021 | $471,000 | -21.1% | 32,254 | +34.9% | 0.19% | -23.0% |
| Q1 2021 | $597,000 | – | 23,907 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |